WuHan Hvsen Biotechnology (300871.SZ): The company has opened a WeChat store.

According to Gelonghui on December 27, WuHan Hvsen Biotechnology (300871.SZ) stated on the investor interactive platform that the company has opened a WeChat store, and you can search for "WuHan Hvsen Protection Mall" mini program on the WeChat platform.

Gelonghui FinanceDec 27 01:21 ET

WuHan Hvsen Biotechnology (300871.SZ): The product portfolio covers areas such as pharmaceuticals for pigs, poultry, aquatic products, ruminants, and pets.

On December 25, Gelonghui reported that WuHan Hvsen Biotechnology (300871.SZ) stated on an investor interaction platform that the company focuses on the research, production, and sales of veterinary pharmaceuticals (including chemical preparations, Active Pharmaceutical Ingredient, Traditional Chinese Medicine preparations), fodder, and additives, with a product mix covering areas such as pig, poultry, aquaculture, ruminants, and pet pharmaceuticals.

Gelonghui FinanceDec 25 01:20 ET

WuHan Hvsen Biotechnology (300871.SZ): The company's Vietnam veterinary drug production base project is currently in the GMP acceptance phase.

On December 20, Gelonghui reported that WuHan Hvsen Biotechnology (300871.SZ) stated on the investor interaction platform that the company's veterinary drug production base project in Vietnam is currently in the GMP acceptance phase.

Gelonghui FinanceDec 20 02:56 ET

Huisheng Biotech: Report for the third quarter of 2024

SZSIOct 29 12:00 ET · Announcements

Wuhan Hvsen Biotechnology (300871.SZ) released its performance for the first three quarters, with a net loss of 47.6583 million yuan.

Wuhan HVSen Biotechnology (300871.SZ) released the third quarter report of 2024, the company's revenue for the first three quarters is 7...

Zhitong FinanceOct 29 10:25 ET

Wuhan Hvsen Biotechnology (300871.SZ): a net loss of 47.6583 million yuan in the first three quarters.

Gelonghui, October 29th - Wuhan Hvsen Biotechnology (300871.SZ) released the third quarter report for 2024, achieving revenue of 0.793 billion yuan in the first three quarters, a year-on-year growth of 14.63%; net income attributable to shareholders of the listed company was -47.6583 million yuan; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -32.3973 million yuan; basic earnings per share was -0.29 yuan.

Gelonghui FinanceOct 29 05:24 ET